{"title":"nus1相关帕金森病的进展及血浆NgBR的诊断潜力","authors":"Lizhi Li, Juanjuan Huang, Yaqin Xiang, Xuxiang Zhang, Qian Xu, Qiying Sun, Zhenhua Liu, Xinxiang Yan, Jinchen Li, Beisha Tang, Jifeng Guo","doi":"10.1111/cns.70549","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>The study aimed to investigate the role of <i>NUS1</i> variants in Parkinson's disease (PD) progression and evaluate plasma Nogo-B receptor (NgBR) as a potential biomarker.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We recruited 228 PD patients, including 38 with <i>NUS1</i> variants (<i>NUS1</i>-PD) and 190 without (GU-PD), and all underwent at least two follow-up visits. Linear mixed-effects models assessed motor and non-motor symptom progression. Plasma NgBR levels were measured in PD, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and healthy controls (HC), and receiver operating characteristic curve analysis evaluated its diagnostic efficacy.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p><i>NUS1</i>-PD demonstrated an earlier age at onset and more severe motor features than GU-PD at baseline. Longitudinal analyses showed similar progression rates of UPDRS III and H&Y stage (off-medication) in <i>NUS1</i>-PD and GU-PD, but a slower progression rate of urinary function in <i>NUS1</i>-PD (<i>p</i> = 0.024). Plasma NgBR levels were higher in PD than in HC, MSA, and PSP, with AUC values of 0.6832, 0.6716, and 0.6628, respectively. Plasma NgBR was associated with UPDRS III (<i>p</i> = 0.006) and cognitive impairment (<i>p</i> = 0.010).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p><i>NUS1</i> variants show no impact on PD progression, while plasma NgBR may serve as a potential biomarker for PD diagnosis and clinical characteristics.</p>\n </section>\n </div>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"31 7","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.70549","citationCount":"0","resultStr":"{\"title\":\"The Progression of NUS1-Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR\",\"authors\":\"Lizhi Li, Juanjuan Huang, Yaqin Xiang, Xuxiang Zhang, Qian Xu, Qiying Sun, Zhenhua Liu, Xinxiang Yan, Jinchen Li, Beisha Tang, Jifeng Guo\",\"doi\":\"10.1111/cns.70549\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>The study aimed to investigate the role of <i>NUS1</i> variants in Parkinson's disease (PD) progression and evaluate plasma Nogo-B receptor (NgBR) as a potential biomarker.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We recruited 228 PD patients, including 38 with <i>NUS1</i> variants (<i>NUS1</i>-PD) and 190 without (GU-PD), and all underwent at least two follow-up visits. Linear mixed-effects models assessed motor and non-motor symptom progression. Plasma NgBR levels were measured in PD, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and healthy controls (HC), and receiver operating characteristic curve analysis evaluated its diagnostic efficacy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p><i>NUS1</i>-PD demonstrated an earlier age at onset and more severe motor features than GU-PD at baseline. Longitudinal analyses showed similar progression rates of UPDRS III and H&Y stage (off-medication) in <i>NUS1</i>-PD and GU-PD, but a slower progression rate of urinary function in <i>NUS1</i>-PD (<i>p</i> = 0.024). Plasma NgBR levels were higher in PD than in HC, MSA, and PSP, with AUC values of 0.6832, 0.6716, and 0.6628, respectively. Plasma NgBR was associated with UPDRS III (<i>p</i> = 0.006) and cognitive impairment (<i>p</i> = 0.010).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p><i>NUS1</i> variants show no impact on PD progression, while plasma NgBR may serve as a potential biomarker for PD diagnosis and clinical characteristics.</p>\\n </section>\\n </div>\",\"PeriodicalId\":154,\"journal\":{\"name\":\"CNS Neuroscience & Therapeutics\",\"volume\":\"31 7\",\"pages\":\"\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.70549\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CNS Neuroscience & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cns.70549\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cns.70549","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
该研究旨在探讨NUS1变异在帕金森病（PD）进展中的作用，并评估血浆Nogo-B受体（NgBR）作为一种潜在的生物标志物。方法：我们招募了228例PD患者，包括38例NUS1变异（NUS1-PD）和190例无（GU-PD），所有患者都进行了至少两次随访。线性混合效应模型评估运动和非运动症状的进展。测定PD、多系统萎缩（MSA）、进行性核上性麻痹（PSP）和健康对照（HC）患者血浆NgBR水平，并通过受试者工作特征曲线分析评价其诊断效果。结果NUS1-PD比GU-PD在基线时表现出更早的发病年龄和更严重的运动特征。纵向分析显示，NUS1-PD和GU-PD患者UPDRS III期和H&；Y期（停药期）进展率相似，但NUS1-PD患者泌尿功能进展率较慢（p = 0.024）。PD组血浆NgBR水平高于HC、MSA和PSP组，AUC值分别为0.6832、0.6716和0.6628。血浆NgBR与UPDRS III （p = 0.006）和认知障碍（p = 0.010）相关。结论NUS1变异对PD的进展无影响，血浆NgBR可能作为PD诊断和临床特征的潜在生物标志物。
The Progression of NUS1-Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR
Aims
The study aimed to investigate the role of NUS1 variants in Parkinson's disease (PD) progression and evaluate plasma Nogo-B receptor (NgBR) as a potential biomarker.
Methods
We recruited 228 PD patients, including 38 with NUS1 variants (NUS1-PD) and 190 without (GU-PD), and all underwent at least two follow-up visits. Linear mixed-effects models assessed motor and non-motor symptom progression. Plasma NgBR levels were measured in PD, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and healthy controls (HC), and receiver operating characteristic curve analysis evaluated its diagnostic efficacy.
Results
NUS1-PD demonstrated an earlier age at onset and more severe motor features than GU-PD at baseline. Longitudinal analyses showed similar progression rates of UPDRS III and H&Y stage (off-medication) in NUS1-PD and GU-PD, but a slower progression rate of urinary function in NUS1-PD (p = 0.024). Plasma NgBR levels were higher in PD than in HC, MSA, and PSP, with AUC values of 0.6832, 0.6716, and 0.6628, respectively. Plasma NgBR was associated with UPDRS III (p = 0.006) and cognitive impairment (p = 0.010).
Conclusion
NUS1 variants show no impact on PD progression, while plasma NgBR may serve as a potential biomarker for PD diagnosis and clinical characteristics.
期刊介绍：
CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
